Treatment of Corneal Vessels: Which Modality is Ideal for an Optimal Result?

Main Article Content

I. Adnane
F. Elalami
I. Er- Rachiq
A. Mchachi
L. Benhmidoune
A. Chakib
R. Rachid
M. Elbelhadji

Abstract

Corneal neovascularization (NV) is characterized by the invasion of new blood vessels into the cornea from the limbus. It is caused by a disruption of the balance between angiogenic and antiangiogenic factors that preserves corneal transparency.

Corneal vessels management has benefited from advances in medical research especially when it comes to the treatment of angiogenesis. The aim of this study is to compare the efficacy of sub conjunctival injections of anti-VEGF with that of fine needle diathermy in the treatment of corneal vessels, and to compare these results with those obtained following the combination of the two therapeutic. A prospective study was conducted in the ophthalmology department of the university hospital center of Casablanca including 60 patients with corneal vessels that we decided to treat randomly by sub conjunctival injections of anti-angiogenic drugs or by fine needle cauterization  a third group of patients was treated by the combination of the two treatments. Our study showed a superiority of the treatment by cauterization compared to the injections of antiangiogenic agents however a better response was observed in the patients having received the two treatments.

Keywords:
Corneal vessels, modality, anti-angiogenic drugs, sub conjunctival injection, corneal neovascularization.

Article Details

How to Cite
Adnane, I., Elalami, F., Rachiq, I. E.-, Mchachi, A., Benhmidoune, L., Chakib, A., Rachid, R., & Elbelhadji, M. (2020). Treatment of Corneal Vessels: Which Modality is Ideal for an Optimal Result?. Asian Journal of Research and Reports in Ophthalmology, 3(4), 9-15. Retrieved from https://journalajrrop.com/index.php/AJRROP/article/view/30118
Section
Original Research Article

References

Azar DT. Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (An American Ophthalmo-logical Society Thesis) Transactions of the American Ophthalmological Society 2006;104:264-302.

Doggart JH. Vascularisation of the cornea. Br J Ophthalmol. 1951;35:160– 167.

Doctor PP, Bhat PV, Foster CS. “Subconjunctival bevacizumab for corneal neovascularization,” Cornea. 2008;27(9): 992–995.

Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmo-logy. 2008;115(6):33–38.

Carrasco MA. Subconjunctivalbevaci-zumab for corneal neovascularization in herpetic stromal keratitis. Cornea. 2008; 27(6):743–745.

Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea. 2008;27(1):70–73.

Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008; 115:33—8.

Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Current Eye Research. 2008;33(1):23– 28.

MacKenzie SE, Tucker WR, Poole TRG. .Bevacizumab (avastin) for corneal neovascularization-corneal light shield soaked application. Cornea. 2009;28(2): 246–247.

Papathanassiou M, Theodossiadis PG, Liarakos VS, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008;145:424-31.

Azar DT, et al. Corneal angiogenic privilege:angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and woundhealing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006; 104:264—302.

Papathanassiou M, Theodossiadis PG, Liarakos VS, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008;145:424-31.

Awadein A, et al. Sub conjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg. 2007;33:1991-3.

Mayer W. Cryotherapy in corneal vascularization. Arch Ophthalmol. 1967;77: 637–41.

Cherry PM, Faulkner JD, Shaver RP, et al. Argon laser treatment of corneal neovascularization. Ann Ophthalmol. 1973; 5:911–20

Lueder GT, Culican S. Yellow dye laser treatment of vascularized corneal stromal scars in pediatric patients. Arch Ophthalmol. 2008;126:564–6

Chidambara T. Pillai, Harminder S. Dua, Parwez Hossain. Fine needle diathermy occlusion of corneal vessels. Invest. Ophthalmol. Vis. Sci. 2000;41(8):2148-2153.

Thatte S. Fine needlediathermy for corneal vascularization. Nepal J Ophthalmol. 2011; 3(5):23-26

Faraj LA, Elalfy MS, Said DG, et al. Br J Ophthalmol. 2014;98:1287–1290.

Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci. 2000;41:2148–2153.

APA Koenig, Yanyan MD, Bock, Felix MD, Kruse, Friedrich E. PhD, Stock, Katja MD, Cursiefen, Claus MD. Angioregressive Pretreatment of Mature Corneal Blood Vessels Before Kerato-plasty: Fine-Needle Vessel Coagulation Combined With Anti-VEGFs, Cornea. 2012;31(8):887-892.

DOI: 10.1097/ICO.0b013e31823f8f7a

Feiziet al. Therapeuticapproaches for corneal neovascularization Eye and Vision. 2017;4:2.

DOI: 10.1186/s40662-017-0094-6